Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Trial Details

NCT ID

NCT04136535

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Pemetrexed
• Carboplatin
• Anlotinib

Locations (sample)

• Shenzhen, shenzhen, China|22.54554,114.0683

Key Eligibility Criteria

• 1\. 18 Years to 75 Years patients voluntarily participate in this study, signed and dated informed consent with good compliance and follow-up; 2. C…
• Blood routine examination criteria (no blood transfusion and blood products within 14 days, no correction by G-CSF and other hematopoietic stimuli):
• i) hemoglobin (HB) ≥90g/L ii) neutrophil absolute (ANC) ≥1.5×109/L iii) platelet (PLT) ≥80×109/L Biochemical tests meet the following criteria i) t…
• Female patients of childbearing age agree that contraceptive measures must be used within the study period and within 8 weeks after the end of the …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.